The CEO of a biopharma firm working on a treatment for a rare, fatal pediatric syndrome says the CMS decision to restrict coverage for an Alzheimer’s drug approved by the FDA makes his job much harder:
“We are working around-the-clock to test our medicine and get it approved by the Food and Drug Administration. But our job just got much harder because of an unprecedented action by another government agency — the Centers for Medicare and Medicaid Services. … If CMS can impugn the FDA, then the ability of small biopharma companies to raise capital is jeopardized.”
